Knee & joint pain — what the evidence shows

You’ve probably done physiotherapy, tried injections, and been told the next real option is a knee replacement — or that you’re “too young” for one, which is its own kind of answer.

That’s the position most people are in when they find this page. It’s a legitimate place to be looking, and it’s also a place where people get sold things.

Nothing here asks you to cancel a surgery or stop what your orthopaedist recommends.

	Conservative care	Conservative care and explore this	Joint replacement	Wait
What it is	Physiotherapy, weight management, analgesics, corticosteroid or hyaluronic acid injections	Continue conservative care; a physician separately assesses whether cell therapy is appropriate	Surgical replacement of the joint surface	Do nothing now; reassess later
Who tends to consider it	Nearly everyone, first	People with mild-to-moderate disease who haven’t responded adequately	People with end-stage disease where replacement is clearly indicated	People whose symptoms fluctuate, or who aren’t ready
What the evidence says	Strongest and longest-standing evidence base	Randomised trials show improvement at 12 months; a share of it is contextual	Well-established, with known outcomes and known risks	Osteoarthritis is generally progressive, but rates vary widely between people
Certainty	High	Low	High	Moderate

These four are not equally studied and the table doesn’t pretend they are. The certainty label under column two is doing real work.

And note what isn’t a column: replacing conservative care with this. No one should offer you that.

What this is. Mesenchymal cells are found in bone marrow, fat and other tissue. They can become bone or cartilage in a laboratory — which is where the word “regenerative” comes from — but that is not what they are believed to do inside a joint.

What the therapy is trying to do. Osteoarthritis is not only worn cartilage. It is also a low-grade inflammatory process involving the whole joint: the lining, the fluid, the bone underneath. Injected mesenchymal cells release signalling molecules that damp that inflammation, and most of the cells are cleared within weeks. The hypothesis being tested is that they change the environment of the joint, not that they rebuild it.

Why researchers became interested. Because the gap in treatment is real. Between painkillers and physiotherapy at one end and joint replacement at the other there is very little — and replacement is a major operation with a finite lifespan, which is why it is usually delayed in younger patients.

Why someone might reasonably discuss it with a physician. Because the honest answer depends on the specific joint, the degree of damage, what has already been tried, and what “better” would mean for that person. None of those are on this page, and all of them are in a consultation.

The clearest signal comes from knee osteoarthritis.

A 2025 meta-analysis of randomised controlled trials found meaningfully better WOMAC scores at twelve months in people who received the cells. A phase 3 trial — randomised, double-blind, placebo-controlled, multicentre — exists, which is more than can be said for most cell therapies. A Cochrane review published in 2025 assessed the field.

For stromal vascular fraction: a phase 3 trial is under way, and a double-blind self-controlled trial — one product in each knee of the same person — reported cartilage repair.

Certainty: low. These numbers may improve or worsen as larger trials report.

Averages, not predictions. Everything above describes groups. It cannot tell you what will happen to your knee.

Researchers measure improvement using validated questionnaires that assess pain, stiffness, and physical function. Across randomized trials, patients receiving mesenchymal stromal cell therapy generally improve more on those measures than patients receiving the comparison treatment. That tells us there is a measurable average benefit across groups, but it does not mean that every patient improves, or that we can predict whether any one individual will. The published studies do not provide a single, reliable percentage that says ‘this many patients benefit,’ because they use different definitions of meaningful improvement.

It doesn’t show that the cells account for all of the improvement. A 2025 meta-analysis measured the share attributable to contextual effects — the needle, the attention, the expectation of getting better. That share is substantial. It’s real improvement that patients genuinely feel; it just isn’t evidence about the cells.

It doesn’t show cartilage regrowth as a reliable outcome. Some studies report structural changes on imaging. Imaging change is not the same as feeling better, and neither is the same as a joint that has been rebuilt.

It doesn’t show durability. Twelve months is where most of the data stops. What happens at five years is not established.

It doesn’t show approval anywhere for this use. No product of this kind is approved for osteoarthritis in the United States.

Certainty: high that these four statements are accurate today.

Understanding your knee.

Approval is applied for, granted country by country, and per condition. No company has completed that process for osteoarthritis.

That’s not the same as “it doesn’t work,” and not the same as “it works.”

→ The full explanation, including what actually protects you →

How much improvement would be worth it. Trials measure change on a questionnaire. Whether that translates into something that matters to you — stairs, sleep, a walk — is a judgement no study makes for you.

How you feel about the contextual share. Some people find “part of this is the ritual” disqualifying. Others reasonably say relief is relief. Both readings are defensible.

What you’d be delaying. If replacement is in your future either way, this is a question about timing, and timing has its own costs and benefits.

What one to three days away from home costs you.

Said before you ask.

• Your osteoarthritis is end-stage and replacement is clearly indicated. This isn’t a substitute for a surgery you need.
• You have an active infection — in the joint or anywhere.
• Your joint is significantly unstable and that hasn’t been addressed.
• You have inflammatory joint disease that isn’t under control.
• You have a medical condition that makes injection procedures unsafe.
• You’re not willing to share your medical records. A responsible review cannot be carried out without them.
• You’re hoping to regrow a destroyed joint. That is not what this does, and anyone implying otherwise is telling you something untrue.

What is not on this list: being over a certain age, being over a certain weight, or having had previous surgery. None of those excludes you automatically — they’re considered individually.

1. Where was this product made, and under what registration?
2. What testing is done on each batch before release?
3. What exactly is in the vial — cell type, count, viability after thawing?
4. Is there a potency assay, and what does it measure?
5. What has been published on this preparation, not the category?
6. How much of the expected improvement is contextual?
7. What would make you tell me I’m not a candidate?

Print this page and take it with you.

About half of health searches are made for another person.

If that’s you: print sections 2 and 9. The options table works in a room with an orthopaedist in it, and the questions work anywhere.

You can begin a review on their behalf — but before any medical record is shared or the clinical review continues, the patient must consent.

1. You send records through a secure upload link — not by email or text. Weight-bearing X-rays are the minimum; MRI if you have one. What the physician needs for this review lists exactly what to gather.
2. An independent physician reviews the case. Some patients are advised that this treatment is not appropriate for their situation.
3. If they consider it appropriate, they speak with you directly and explain any applicable fees at that point. Human Paths does not set, publish, collect or process payment for healthcare services.
4. You decide.

What the commitment looks like: typically one trip, staying 1 to 3 days, depending on the procedure and follow-up. The treating physician confirms the final schedule after reviewing your case.

The request form is linked from the home page, deliberately not from here: reading the evidence and asking for a review are two separate steps.

---